DOSE LEVEL 1 - Patient characteristics

Patient ID	Age (years)	Gender	Tumor	Extrahepatic metastases	Site(s) of Active Disease	Response
DL1.CAR 1	3	Female	HB	+	Liver and lungs	Progressive disease
DL1.CAR 2	7	Female	HC-NOS	+	Lungs	Stable disease
DL1.CAR 3	13	Female	HB	+	Lungs	Progressive disease
DL1.CAR 4	68	Female	HCC	+	Liver, retroperitoneal nodes, and para-aortic mass	Progressive disease
DL1.CAR 5	67	Female	HCC	+	Liver and bone	Stable disease
DL1.CAR 6	50	Female	HCC	+	Liver and lungs	Stable disease

DOSE LEVEL 2 - Patient characteristics

CAR 1	4	Male	HB	+	Lungs	Progressive disease
CAR 2	4	Male	HB	+	Lungs	Progressive disease
CAR 3	4	Male	HB	+	Lungs	Stable disease
CAR 4	62	Female	HCC	+	Liver and lungs	Progressive disease
CAR 5	63	Male	HCC	+	Liver with invasion of portal node and abdominal wall	Stable disease
CAR 6	72	Male	HCC	+	Liver and retroperitoneal lymph node	Stable disease
15.CAR 1	20	Male	HCC	+	Liver, lungs, and bone	Partial response
15.CAR 2	8	Female	HCC	+	Liver and lungs	Progressive disease
15.CAR 3	10	Male	HCC	+	Liver and lungs	Progressive disease
15.CAR 4	11	Female	HC-NOS	+	Liver and lungs	Stable disease
15.CAR 5	11	Male	HC-NOS	-	Liver	Progressive disease
15.CAR 6	6	Female	WT	+	Liver and Lungs	Progressive disease
15.CAR 7	20	Female	NET	+	Pancreas, Liver	Stable disease
15.CAR 8	11	Male	ERMS	+	Right Nasopharynx	Partial response
15.CAR 9	68	Male	HCC	-	Liver	Partial response
15.CAR 10	65	Male	HCC	+	Liver and Retroperitoneal lymph node	Stable disease
15.CAR 11	32	Male	YST	+	Mediastinum, Axillary nodes, and Bone	Stable disease
15.CAR 12	69	Male	HCC	-	Liver	Partial response

HCC: Hepatocellular carcinoma. HC-NOS: Hepatocellular neoplasm not otherwise specified. Cy: cyclophosphamide. Flu: Fludarabine. YST: Yolk sac tumor; WT: Wilms Tumor; NET: neuroendocrine tumor of the pancreas, ERMS: Embryonal rhabdomyosarcoma.

Extended data 1. Patient characteristics: Patients infused CAR on DL1 (top section) and with CAR or 15.CAR T cell on DL2 (bottom section) are described for general demographics, underlying malignancy, extent of disease and response to therapy.